Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-15

FDA Approved: REYVOW — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for Reyvow (lasmiditan) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • REYVOW (Lasmiditan)

Snippet

SUPPL AP for REYVOW (LASMIDITAN)